Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoSTOP-IT: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Muscle-invasive Bladder Cancer
NCT06571708Phase 2Terminated
- Sponsor
- Columbia University
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of fianlimab in bladder cancer, sponsored by Columbia University. Started Aug 2025; status: terminated.
02
Drugs
fianlimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT06571708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06571708.